Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance

Infection, Genetics and Evolution

Volumn 10, Issue 2, 2010, Pages 346-349

  Zimic, Mirko ^a   Sheen, Patricia ^a   Quiliano, Miguel ^a   Gutierrez, Andrés ^a   Gilman, Robert H ^a,b  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Mutations; pncA; Pyrazinamidase; Pyrazinamide; Resistance; Tuberculosis

Indexed keywords

BACTERIAL ENZYME; PYRAZINAMIDASE; PYRAZINAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE CLUSTER; GENETIC ASSOCIATION; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE;

AMIDOHYDROLASES; AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BINDING SITES; CLUSTER ANALYSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PERU; PROTEIN STRUCTURE, SECONDARY; PYRAZINAMIDE; STATISTICS, NONPARAMETRIC; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 77149162022     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.11.016     Document Type: Article

References (40)

1. Aragon L.M., Garrigo M., Moreno C., Espanol M., and Coll P. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. J. Antimicrob. Chemother. 60 (2007) 655-657
2. Barco P., Cardoso R.F., Hirata R.D., Leite C.Q., Pandolfi J.R., Sato D.N., Shikama M.L., de Melo F.F., Mamizuka E.M., Campanerut P.A., and Hirata M.H. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 58 (2006) 930-935
3. Bishop K.S., Blumberg L., Trollip A.P., Smith A.N., Roux L., York D.F., and Kiepiela P. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuberc. Lung Dis. 5 (2001) 952-957
4. Brown T.J., Tansel O., and French G.L. Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J. Med. Microbiol. 49 (2000) 651-656
5. Cheng S.J., Thibert L., Sanchez T., Heifets L., and Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44 (2000) 528-532
6. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163 (2003) 1009-1021
7. Denkin S., Volokhov D., Chizhikov V., and Zhang Y. Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J. Med. Microbiol. 54 (2005) 1127-1131
8. Du X., Wang W., Kim R., Yakota H., Nguyen H., and Kim S.H. Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 40 (2001) 14166-14172
9. Endoh T., Yagihashi A., Uehara N., Kobayashi D., Tsuji N., Nakamura M., Hayashi S., Fujii N., and Watanabe N. Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. Epidemiol. Infect. 128 (2002) 337-342
10. Escalante P., Ramaswamy S., Sanabria H., Soini H., Pan X., Valiente-Castillo O., and Musser J.M. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tubercle Lung Dis. 79 (1998) 111-118
11. Girling D. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. Tubercle 65 (1984) 1-4
12. Heifets L., and Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145 (1992) 1223-1225
13. Hirano K., Takahashi M., Kazumi Y., Fukasawa Y., and Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercle Lung Dis. 78 (1997) 117-122
14. Hou L., Osei-Hyiaman D., Zhang Z., Wang B., Yang A., and Kano K. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect. 124 (2000) 227-232
15. Huang T.S., Lee S.S., Tu H.Z., Huang W.K., Chen Y.S., Huang C.K., Wann S.R., Lin H.H., and Liu Y.C. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47 (2003) 3672-3673
16. Jureen P., Werngren J., Toro J.C., and Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52 (2008) 1852-1854
17. Lee A.S., Tang L.L., Lim I.H., and Wong S.Y. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6 (2002) 48-51
18. Lemaitre N., Callebaut I., Frenois F., Jarlier V., and Sougakoff W. Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem. J. 353 (2001) 453-458
19. Lemaitre N., Sougakoff W., Truffot-Pernot C., and Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother. 43 (1999) 1761-1763
20. Martin A., Takiff H., Vandamme P., Swings J., Palomino J.C., and Portaels F. A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J. Antimicrob. Chemother. 58 (2006) 327-331
21. Marttila H.J., Marjamaki M., Vyshnevskaya E., Vyshnevskiy B.I., Otten T.F., Vasilyef A.V., and Viljanen M.K. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43 (1999) 1764-1766
22. McCammon M.T., Gillette J.S., Thomas D.P., Ramaswamy S.V., Rosas I.I., Graviss E.A., Vijg J., and Quitugua T.N. Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region. Antimicrob. Agents Chemother. 49 (2005) 2210-2217
23. Mestdagh M., Fonteyne P.A., Realini L., Rossau R., Jannes G., Mijs W., De Smet K.A., Portaels F., and Van den Eeckhout E. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43 (1999) 2317-2319
24. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66 (1985) 219-225
25. Miyagi C., Yamane N., Yogesh B., Ano H., and Takashima T. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn. Microbiol. Infect. Dis. 48 (2004) 111-116
26. Mphahlele M., Syre H., Valvatne H., Stavrum R., Mannsaker T., Muthivhi T., Weyer K., Fourie P.B., and Grewal H.M. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46 (2008) 3459-3464
27. Park S.K., Lee J.Y., Chang C.L., Lee M.K., Son H.C., Kim C.M., Jang H.J., Park H.K., and Jeong S.H. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect. Dis. 1 (2001) 4
28. Portugal I., Barreiro L., Moniz-Pereira J., and Brum L. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48 (2004) 2736-2738
29. Post F.A., Willcox P.A., Mathema B., Steyn L.M., Shean K., Ramaswamy S.V., Graviss E.A., Shashkina E., Kreiswirth B.N., and Kaplan G. Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J. Infect. Dis. 190 (2004) 99-106
30. Rodrigues Vde F., Telles M.A., Ribeiro M.O., Cafrune P.I., Rossetti M.L., and Zaha A. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 49 (2005) 444-446
31. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., and Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41 (1997) 540-543
32. Sekiguchi J.I., Nakamura T., Miyoshi-Akiyama T., Kirikae F., Kobayashi I., Augustynowicz-Kopec E., Zwolska Z., Morita K., Suetake T., Yoshida H., Kato S., Mori T., and Kirikae T. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 45 (2007) 2802-2907
33. Sheen P., Ferrer P., Gilman R.H., López-Llano J., Fuentes P., Valencia E., and Zimic M. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis 89 (2009) 109-113
34. Sheen P., Méndez M., Gilman R.H., Peña L., Caviedes L., Zimic M.J., Zhang Y., Moore D.A., and Evans C.A. A sputum PCR-SSCP test for same-day detection of pyrazinamide resistance in tuberculosis patients. J. Clin. Microbiol. 47 (2009) 2937-2943
35. Sreevatsan S., Pan X., Zhang Y., Kreiswirth B.N., and Musser J.M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41 (1997) 636-640
36. Suzuki Y., Suzuki A., Tamaru A., Katsukawa C., and Oda H. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. J. Clin. Microbiol. 40 (2002) 501-507
37. Tracevska T., Nodieva A., and Skenders G. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob. Agents Chemother. 48 (2004) 3209-3210
38. Zhang Y., and Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7 (2003) 6-21
39. Zhang Y., Scorpio A., Nikaido H., and Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181 (1999) 2044-2049
40. Zhang Y., Wade M.M., Scorpio A., Zhang H., and Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52 (2003) 790-795